Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 3.93B | 3.90B | 3.66B | 3.37B | 3.22B | 2.71B |
Gross Profit | 2.41B | 2.38B | 2.19B | 2.00B | 1.89B | 1.57B |
EBITDA | 1.29B | 1.28B | 1.22B | 1.01B | 1.04B | 793.81M |
Net Income | 894.97M | 887.87M | 845.04M | 679.09M | 744.85M | 581.78M |
Balance Sheet | ||||||
Total Assets | 3.21B | 3.29B | 3.26B | 2.75B | 2.44B | 2.29B |
Cash, Cash Equivalents and Short-Term Investments | 163.97M | 288.27M | 453.93M | 112.55M | 144.45M | 383.93M |
Total Debt | 1.06B | 986.95M | 1.07B | 1.35B | 923.70M | 908.48M |
Total Liabilities | 1.77B | 1.70B | 1.78B | 2.14B | 1.75B | 1.66B |
Stockholders Equity | 1.45B | 1.60B | 1.48B | 608.74M | 689.99M | 632.09M |
Cash Flow | ||||||
Free Cash Flow | 837.70M | 798.08M | 772.88M | 394.15M | 636.00M | 540.44M |
Operating Cash Flow | 968.38M | 929.00M | 906.51M | 542.98M | 755.55M | 648.06M |
Investing Cash Flow | -129.73M | -207.06M | -125.25M | -195.35M | -292.97M | -109.38M |
Financing Cash Flow | -1.06B | -878.07M | -442.00M | -370.94M | -697.41M | -248.42M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | $43.65B | 50.15 | 59.33% | ― | 5.56% | 4.66% | |
79 Outperform | $34.22B | 29.71 | 18.88% | 0.82% | 0.56% | -4.08% | |
79 Outperform | $19.71B | 22.32 | 13.35% | 1.81% | 9.38% | 6.43% | |
73 Outperform | $20.94B | 31.91 | 40.82% | ― | 2.57% | 8.31% | |
68 Neutral | $11.89B | 39.89 | 3.82% | 0.28% | 1.62% | 78.53% | |
64 Neutral | $25.06B | 30.07 | -680.23% | ― | 1.18% | 12.34% | |
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% |
On May 7, 2025, IDEXX Laboratories, Inc. made significant amendments to its corporate governance structure. The company filed a Certificate of Elimination to remove the designation of its Series A Junior Participating Preferred Stock and amended its Certificate of Incorporation to eliminate supermajority voting provisions and allow officer exculpation as per Delaware law. Additionally, the company updated its By-Laws to reflect these changes and establish Delaware courts as the exclusive forum for certain legal actions. These amendments, approved during the 2025 Annual Meeting, aim to streamline corporate governance and align with current legal standards, potentially impacting shareholder engagement and corporate decision-making processes.